China Biopharmaceutical: The national Class 1 innovative drug TQB2102 injection “HER2 double epitope double antibody ADC” independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of the Group, has submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center and has been accepted for use in adult breast cancer patients with unresectable or metastatic HER2 low expression who have not received chemotherapy in the recurrent or metastatic stage of the disease. Previously, this indication was included by CDE as a breakthrough treatment.

China Biopharmaceutical: The national Class 1 innovative drug TQB2102 injection “HER2 double epitope double antibody ADC” independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of the Group, has submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center and has been accepted for use in adult breast cancer patients with unresectable or metastatic HER2 low expression who have not received chemotherapy in the recurrent or metastatic stage of the disease. Previously, this indication was included by CDE as a breakthrough treatment.